Elena Avgoustou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Elena Avgoustou has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Dimitris Kounatidis
Diabetes Center, First Propaedeutic Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece
2 shared publications - Natalia G. Vallianou
First Department of Internal Medicine, Sismanogleio General Hospital, Athens, Greece
2 shared publications - Alexandros Skourtis
Department of Internal Medicine, Evangelismos General Hospital, 10676 Athens, Greece
1 shared publication - Despoina Avramidou
Second Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Hippokratio General Hospital, Vasilissis Sofias 114, 11527 Athens, Greece
1 shared publication - Dimitrios Vassilopoulos
Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Athens, Greece
1 shared publication - Evgenia Plenga
Department of Internal Medicine, Hippokration General Hospital, Athens, Greece
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 14 January 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (2) , 169
Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment
Obesity has emerged as a global epidemic with far-reaching health complications, including its role as an independent risk factor for chronic kidney disease (CKD). Increasing evidence suggests that obesity contributes to CKD through multiple mechanisms, including chronic inflammation, hemodynamic alterations, insulin resistance, and lipid accumulation. These processes can culminate in histopathological changes collectively referred to as obesity-related glomerulopathy (ORG). This review aims to provide a comprehensive overview of the current knowledge regarding the prevalence, clinical manifestations, and pathophysiology of ORG. Furthermore, we emphasize the importance of identifying key biomarkers that facilitate the early detection of ORG. Finally, we explore emerging therapeutic strategies that offer promise in mitigating this growing global health crisis.
- 14 January 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (2) , 169
Top Cited PapersOpen AccessObesity-Related Chronic Kidney Disease: From Diagnosis to Treatment
Obesity has emerged as a global epidemic with far-reaching health complications, including its role as an independent risk factor for chronic kidney disease (CKD). Increasing evidence suggests that obesity contributes to CKD through multiple mechanisms, including chronic inflammation, hemodynamic alterations, insulin resistance, and lipid accumulation. These processes can culminate in histopathological changes collectively referred to as obesity-related glomerulopathy (ORG). This review aims to provide a comprehensive overview of the current knowledge regarding the prevalence, clinical manifestations, and pathophysiology of ORG. Furthermore, we emphasize the importance of identifying key biomarkers that facilitate the early detection of ORG. Finally, we explore emerging therapeutic strategies that offer promise in mitigating this growing global health crisis.
- Open Access
- 30 July 2024
- Published by Elsevier in Metabolism Open
- Vol. 23, 100307
Incidental detection of hereditary bisalbuminemia in a patient with positive DAT coombs: A case-based review
- 30 July 2024
- Published by Elsevier in Metabolism Open
- Vol. 23, 100307
Open AccessIncidental detection of hereditary bisalbuminemia in a patient with positive DAT coombs: A case-based review
- 18 October 2023
- Published by Springer Nature in Rheumatology International
- Vol. 44 (2) , 363-367
Pneumocystosis in a patient with rheumatoid arthritis on adalimumab therapy: a case-based review
Pneumocystis jirovecii pneumonia (PJP) is a potentially fatal type of pneumonitis, which may have devastating consequences. Typically, it occurs in immunocompromised patients, with the natural history varying depending on the presence or not of HIV infection. Staining and polymerase chain reaction (PCR) testing in induced sputum or bronchoalveolar lavage (BAL) is the cornerstone of the diagnosis, while trimethoprim-sulfamethoxazole is the treatment of choice. The etiological association of biologic agents with the occurrence of PJP is not entirely clear. Adalimumab is a fully human monoclonal anti-TNF-alpha antibody, which has been introduced relatively recently in the treatment of autoimmune inflammatory diseases, such as rheumatoid arthritis. In contrast to other biologic agents, such as Alemtuzumab or Infliximab, there are a small number of reports that support the drug's ability to trigger the occurrence of PJP. Hereby, we present a 53-year-old female patient with a medical history of rheumatoid arthritis on Adalimumab therapy, who developed PJP and we will discuss the main characteristics of PJP and the possible contribution of biologics to the occurrence of the infection.
- 18 October 2023
- Published by Springer Nature in Rheumatology International
- Vol. 44 (2) , 363-367
Pneumocystosis in a patient with rheumatoid arthritis on adalimumab therapy: a case-based review
Pneumocystis jirovecii pneumonia (PJP) is a potentially fatal type of pneumonitis, which may have devastating consequences. Typically, it occurs in immunocompromised patients, with the natural history varying depending on the presence or not of HIV infection. Staining and polymerase chain reaction (PCR) testing in induced sputum or bronchoalveolar lavage (BAL) is the cornerstone of the diagnosis, while trimethoprim-sulfamethoxazole is the treatment of choice. The etiological association of biologic agents with the occurrence of PJP is not entirely clear. Adalimumab is a fully human monoclonal anti-TNF-alpha antibody, which has been introduced relatively recently in the treatment of autoimmune inflammatory diseases, such as rheumatoid arthritis. In contrast to other biologic agents, such as Alemtuzumab or Infliximab, there are a small number of reports that support the drug's ability to trigger the occurrence of PJP. Hereby, we present a 53-year-old female patient with a medical history of rheumatoid arthritis on Adalimumab therapy, who developed PJP and we will discuss the main characteristics of PJP and the possible contribution of biologics to the occurrence of the infection.